Author

J. Tasnim

h-index 9 View on Semantic Scholar

We have 3 of 62 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Corrigendum to “Computational screening of Sophora flavescens phytochemicals as potential aromatase inhibitors: Molecular docking, ADMET, Network pharmacology, Molecular dynamics simulation, and DFT studies” [Pharmaceutic. Sci. Adv. 4 (2026) 100108]

[This corrects the article DOI: 10.1016/j.pscia.2026.100108.].

Laiba Rashid, J. Tasnim, M. M. Mehedi Hasan et al. · Pharmaceutical Science Advan... · 0 citations

Open access Sep 2026

Association of MDM2 rs2279744 and rs937282 polymorphisms with breast cancer susceptibility and circulating MDM2 and p53 levels in Bangladeshi women: A case-control study

Background The MDM2–p53 signaling pathway plays a central role in tumor suppression, and genetic variants that disrupt this pathway may influence breast cancer (BC) susceptibility. However, data from South Asian populations, particularly Bangladesh, remain limited. Methods A case–control study was conducted in Banglade...

M. H. Chowdhury, Farzana Islam, A. Khan et al. · PLoS ONE · 0 citations

Open access Jul 2026

In silico identification of novel PTP1B inhibitors by the investigation of molecular mechanism, QSAR, and DFT studies

Overall, the synergy of the computational methods has made CID 44560744 a lead scaffold for the development and optimization of selective PTP1B inhibitors for T2DM therapy.

Humaira Zulfiqar, Samira Akter, J. Tasnim et al. · In Silico Pharmacology · 1 citation